Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing’s Disease
Open Access
- 18 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
Abstract
Purpose: To investigate the role of heat-shock protein Hsp90 in adrenocorticotropic hormone (ACTH)-secreting cells, and to explore the potential clinical application of an inhibitor of Hsp90, 17-N-allylamino-17-demethoxygeldanamycin(17-AAG) in corticotropinomas [also known as “Cushing’s disease” (CD)]. Methods: Culture of mouse pituitary tumor [AtT-20/D16v-F2 (ATCC® CRL-1795™)] cells and human pituitary ACTH-secreting tumor cells were employed. Hepatocellular carcinoma cell line (HLE) was used to evaluate EGFR inhibition by 17-AAG. Cell viability was evaluated using a commercial kit. The ACTH level was measured by a radioimmunoassay. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to measure expression of proopiomelanocortin (POMC) mRNA. Western blotting was done to measure protein levels. Results: 17-AAG suppressed the viability and proliferation, and promoted the apoptosis, of AtT-20/D16v-F2 cells. 17-AAG suppressed the synthesis and secretion of ACTH in AtT-20/D16v-F2 cells and down-regulated POMC transcription. 17-AAG acted in a similar pattern upon treatment with human pituitary ACTH-secreting tumor cells. Inhibition by 17-AAG was stronger in human pituitary ACTH-secreting tumor cells carrying the ubiquitin-specific protease-8 (USP8) mutant in comparison with cells carrying wild-type USP8. Conclusions: The HSP90 inhibitor 17-AAG reduced the viability and secretory function of human pituitary ACTH-secreting tumor cells, and tumor cells carrying the USP8 mutant were more sensitive to 17-AAG than tumor cells carrying wild-type USP8. 17-AAG could be a potential treatment option for CD.Funding Information
- National Science Fund for Distinguished Young Scholars
- Innovative Research Group Project of the National Natural Science Foundation of China
- Innovative Research Group Project of the National Natural Science Foundation of China
This publication has 28 references indexed in Scilit:
- THERAPY IN ENDOCRINE DISEASE: Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a reviewActa Endocrinologica, 2012
- A 12-Month Phase 3 Study of Pasireotide in Cushing's DiseaseThe New England Journal of Medicine, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasJCI Insight, 2011
- HSP90 Inhibitors as Therapy for Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2011
- Tanespimycin as Antitumor TherapyClinical Lymphoma Myeloma and Leukemia, 2011
- Targeting Hsp90: small-molecule inhibitors and their clinical developmentCurrent Opinion in Pharmacology, 2008
- The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapyNature Reviews Cancer, 2008
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorsNature, 2003
- Low Expression of the Cell Cycle Inhibitor p27Kip1 in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary TumorsJournal of Clinical Endocrinology & Metabolism, 1999